Cargando…

Pneumococcal vaccination in autoimmune rheumatic diseases

Streptococcus pneumoniae is the leading cause of the community-acquired pneumonia. The mortality rate of invasive pneumococcal infections is high. Immunocompromised patients suffering from autoimmune inflammatory rheumatic diseases (AIRD) have a high risk for acquiring these infections. Protection a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rákóczi, Éva, Szekanecz, Zoltan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Treatments
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604716/ https://www.ncbi.nlm.nih.gov/pubmed/28955497 http://dx.doi.org/10.1136/rmdopen-2017-000484

Ejemplares similares

Cognitive dysfunction in autoimmune rheumatic diseases
por: Oláh, Csaba, et al.
Publicado: (2020)

Immune-Regulatory Mechanisms in Systemic Autoimmune and Rheumatic Diseases
por: Nakken, Britt, et al.
Publicado: (2012)

Efficacy and safety of intra-articular therapies in rheumatic and musculoskeletal diseases: an overview of systematic reviews
por: Rodriguez-García, Sebastián Cruz, et al.
Publicado: (2021)

Effectiveness and waning of protection with the BNT162b2 vaccine against the SARS-CoV-2 Delta variant in immunocompromised individuals
por: Szekanecz, Zoltán, et al.
Publicado: (2023)

Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine
por: Rákóczi, Éva, et al.
Publicado: (2023)

Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study
por: Winthrop, Kevin, et al.
Publicado: (2022)

Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider
por: Krieckaert, Charlotte, et al.
Publicado: (2022)

Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database
por: Stajszczyk, Marcin, et al.
Publicado: (2023)

Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study
por: van der Togt, Céleste J T, et al.
Publicado: (2023)

Non-pharmacological interventions to promote work participation in people with rheumatic and musculoskeletal diseases: a systematic review and meta-analysis from the EULAR taskforce on healthy and sustainable work participation
por: Butink, Maarten H P, et al.
Publicado: (2023)

Adaptive Immunity to Viruses: What Did We Learn from SARS-CoV-2 Infection?
por: Vályi-Nagy, István, et al.
Publicado: (2022)

Influenza, Pneumococcal and Herpes Zoster Vaccination Rates in Patients with Autoimmune Inflammatory Rheumatic Diseases
por: Krasselt, Marco, et al.
Publicado: (2023)

Editorial: Comorbidity Burden in Rheumatic Diseases
por: Nikiphorou, Elena, et al.
Publicado: (2018)

Vascular involvement in rheumatic diseases: 'vascular rheumatology'
por: Szekanecz, Zoltán, et al.
Publicado: (2008)

Self-evidence-based digital care programme improves health-related quality of life in adults with a variety of autoimmune diseases and long COVID: a retrospective study
por: Bundy, Nicole, et al.
Publicado: (2023)

Third dose corrects waning immunity to SARS-CoV-2 mRNA vaccines in immunocompromised patients with immune-mediated inflammatory diseases
por: Cheung, Michelle W, et al.
Publicado: (2022)

Secukinumab does not impair the immunogenic response to the influenza vaccine in patients
por: Richi, Patricia, et al.
Publicado: (2019)

Vaccinations in autoimmune inflammatory rheumatic diseases
por: Szenborn, Leszek
Publicado: (2016)

Treating neglected tropical diseases
por: Hopkins, Adrian
Publicado: (2013)

Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine
por: Lems, Willem, et al.
Publicado: (2021)

Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF
por: Cachen, Laurie, et al.
Publicado: (2022)

JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications
por: Russell, Mark D, et al.
Publicado: (2023)

Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis
por: Gehin, Johanna Elin, et al.
Publicado: (2021)

Real-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung disease
por: Niitsu, Takayuki, et al.
Publicado: (2023)

Nine-year follow-up of local implantation of autologous skeletal myoblasts in a patient with coronary heart disease
por: Zhang, Dingguo, et al.
Publicado: (2013)

Autoimmune Rheumatic Diseases
por: Anaya, Juan-Manuel, et al.
Publicado: (2014)

Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors
por: Pitt, Bertram, et al.
Publicado: (2015)

Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study
por: Barbulescu, Andrei, et al.
Publicado: (2020)

The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction
por: Brownell, Nicholas K, et al.
Publicado: (2021)

Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview
por: Toussirot, Éric, et al.
Publicado: (2016)

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre‐specified subgroup with heart failure
por: Rossignol, Patrick, et al.
Publicado: (2020)

Non-surgical and surgical treatments for rotator cuff disease: a pragmatic randomised clinical trial with 2-year follow-up after initial rehabilitation
por: Cederqvist, Sanna, et al.
Publicado: (2021)

Is methotrexate safe for men with an immune-mediated inflammatory disease and an active desire to become a father? Results of a prospective cohort study (iFAME-MTX)
por: Perez-Garcia, Luis Fernando, et al.
Publicado: (2023)

Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting
por: Liang, Huifang, et al.
Publicado: (2019)

Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials
por: Curtis, Jeffrey R, et al.
Publicado: (2019)

Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies
por: Reinisch, Walter, et al.
Publicado: (2023)

Effectiveness of inactivated influenza vaccine in autoimmune rheumatic diseases treated with disease-modifying anti-rheumatic drugs
por: Nakafero, Georgina, et al.
Publicado: (2020)

Update on COVID-19 vaccines and autoimmune-mediated rheumatic diseases
por: Suresh, Lakshmanan
Publicado: (2021)

Autoimmune inflammatory rheumatic diseases post-COVID‐19 vaccination
por: Safary, Azam, et al.
Publicado: (2022)

Vaccination of patients with autoimmune inflammatory rheumatic disease: physicians’ perspectives
por: Moon, Ki Won
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0l8co7vmb77bpojupr2o5rtgci